TriSalus Life Sciences (TLSIW) Notes Payables (2021 - 2023)

TriSalus Life Sciences (TLSIW) has 3 years of Notes Payables data on file, last reported at $1.6 million in Q2 2023.

• For the quarter ending Q2 2023, Notes Payables rose 66.65% year-over-year to $1.6 million; the trailing twelve-month figure through Jun 2023 stood at $1.6 million (up 66.65% YoY), and the FY2022 full-year result was $944000.0, up 73.53% from the prior year.
• Notes Payables for Q2 2023 stood at $1.6 million, up from $1.4 million in the prior quarter.
• Across five years, Notes Payables topped out at $1.6 million in Q2 2023 and bottomed at $544000.0 in Q4 2021.
• The 3-year median for Notes Payables is $944000.0 (2022), against an average of $1.0 million.
• The widest annual swing landed in 2022, when Notes Payables soared 73.53%; it then surged 66.65% in 2023.
• A 3-year view of Notes Payables shows it stood at $544000.0 in 2021, then jumped by 73.53% to $944000.0 in 2022, then soared by 66.65% to $1.6 million in 2023.
• The last three Notes Payables figures came in at $1.6 million (Q2 2023), $1.4 million (Q1 2023), and $944000.0 (Q4 2022), per Business Quant data.

Peer Comparison